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The global prevalence of type 2 diabetes mellitus 
(T2DM) continues to increase at a considerable rate, 
with a corresponding rise in morbidity and mortal-
ity, which places a growing burden on health- care 
systems1. Insulin resistance is a key antecedent patho-
physiological feature in T2DM. The great majority 
of patients with T2DM are also obese, and obesity is 
far and away the major cause of insulin resistance in 
humans. Thus, obesity and T2DM are closely linked, 
and the parallel worldwide increases in obesity rates 
are the main driver of the T2DM epidemic. Many of 
these individuals with obesity are prediabetic, in that 
they will eventually develop T2DM. The rates of con-
version can be 2–10% per year, depending on the popu-
lation under study and the means of assessment2,3. 
However, not all individuals with obesity develop 
T2DM. In those patients who do progress, a second 
metabolic defect occurs in addition to insulin resis-
tance, involving β- cell dysfunction4,5. In T2DM, β- cells 
can no longer secrete excessive amounts of insulin to 
compensate for the insulin resistance, and hypergly-
caemia ensues. There is an enormous literature avail-
able on β- cell dysfunction in T2DM. For example, 
glucotoxicity, lipotoxicity, genetic defects, oxidative 
responses, endoplasmic reticulum (ER) stress, inflam-
mation and other mechanisms have all been impli-
cated as causally related to decreased insulin secretion 
from β- cells6.
Obesity is well known to confer a state of chronic 
low- grade inflammation, particularly in adipose tissue 
and liver7–9. Many studies point to this inflammatory 
state as an underlying mechanism for the development 
of insulin resistance in obesity and T2DM. A num-
ber of papers have now demonstrated that this chronic 
tissue inflammatory state also occurs in pancreatic 
islets10–12. Islet inflammation has been described in a 
variety of mouse models of obesity and T2DM as well 
as in human islets from patients with obesity and/or 
T2DM10. The mechanisms leading to islet inflamma-
tion are incompletely understood, but it is likely that islet 
inflammation contributes to the β- cell dysfunction that 
characterizes T2DM.
In this Review, we focus on the concept of islet inflam-
mation, with particular attention paid to the innate 
immune system (that is, macrophages). We discuss the 
distribution and accumulation of macrophages in pan-
creatic islets in normal and obese conditions and how 
macrophages influence β- cell abnormalities (Box 1).
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Abstract | Chronic, unresolved tissue inflammation is a well- described feature of obesity, type 2 
diabetes mellitus (T2DM) and other insulin- resistant states. In this context, adipose tissue 
and liver inflammation have been particularly well studied; however, abundant evidence 
demonstrates that inflammatory processes are also activated in pancreatic islets from obese 
animals and humans with obesity and/or T2DM. In this Review, we focus on the characteristics 
of immune cell- mediated inflammation in islets and the consequences of this with respect to 
β-cell function. In contrast to type 1 diabetes mellitus, the dominant immune cell type causing 
inflammation in obese and T2DM islets is the macrophage. The increased macrophage accumulation 
in T2DM islets primarily arises through local proliferation of resident macrophages, which then 
provide signals (such as platelet- derived growth factor) that drive β- cell hyperplasia (a classic 
feature of obesity). In addition, islet macrophages also impair the insulin secretory capacity of 
β-cells. Through these mechanisms, islet- resident macrophages underlie the inflammatory 
response in obesity and mechanistically participate in the β- cell hyperplasia and dysfunction 
that characterizes this insulin- resistant state. These findings point to the possibility of 
therapeutics that target islet inflammation to elicit beneficial effects on β- cell function 
and glycaemia.
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Macrophages in pancreatic islets
During embryonic development and at steady state. 
Tissue macrophages can be acquired during develop-
ment or can differentiate from circulating monocytes13. 
Studies in mice show that, during embryonic develop-
ment, macrophages in the pancreas are derived from 
yolk sac- derived primitive haematopoiesis14. These pancre-
atic macrophages are found in close proximity to insulin- 
positive β- cells14, and additional studies suggested that 
these macrophages are involved in islet morphogenesis15. 
Consistent with this idea, a mouse model of osteopetrosis 
(op/op mice), which lacks colony- stimulating factor 1 
(CSF1) and has a deficit in macrophage development, 
showed decreased pancreatic islet development and 
β-cell expansion15,16.
Pancreatic macrophages display heterogeneous 
pheno types depending on developmental stage15,17, 
anatomical location12,17 or the metabolic setting12. 
With respect to the latter, using immunostaining of 
macrophage- specific plasma membrane proteins (for 
example, the adhesion F4/80 and the integrin CD11c) 
and flow cytometry analyses, researchers found that 
pancreatic islets harboured two phenotypically distinct 
macrophage subsets at steady state. A F4/80loCD11c+ 
population was enriched within the islets (intra- islet 
macrophages), whereas F4/80hiCD11c– macrophages 
largely resided in the peripheral islet area (known as 
peri- islet macrophages)12. Knowledge about the role of 
these pancreas- resident or islet- resident macrophages 
at steady state remains incomplete. In addition to pro-
moting islet organogenesis16,17, how pancreatic macro-
phages participate in tissue homeostasis and the function 
of β- cells remains to be fully defined.
Inflammation in T2DM islets. Tissue inflammation 
is characterized by the accumulation and differenti-
ation of various types of immune cell in local patho-
logical lesions18–21. Macrophages are key cell types that 
orchestrate the initiation, specification and resolution 
of tissue- specific inflammation9,22,23 (Box 2). Numerous 
studies have revealed that macrophage infiltration is 
increased in T2DM islets and that the number of islet- 
resident macro phages generally correlates with the 
degree of β-cell dysfunction24–29. Of note, insulitis is well 
known as a feature common to both type 1 diabetes mel-
litus (T1DM) and T2DM islets derived from humans; 
however, a clear distinction exists between these two 
conditions — in T2DM islet inflammation, macro-
phages dominate, whereas both innate and adaptive 
immune cells are heavily involved in T1DM islets11. 
For example, the number of CD68+ (a macrophage- 
specific plasma membrane protein) macrophages is 
reportedly increased in human and mouse T2DM 
islets without changes in the number of CD3+ T cells24. 
Moreover, the same study found that the majority of 
CD68+ macrophages were positive for tissue- resident 
macrophage markers, such as CD163 and HLA2. 
In another study, the number of CD68 and indu cible 
nitric oxide synthase double- positive macrophages 
increased in islet amyloid polypeptide (IAPP)-positive 
T2DM islets, without changes in numbers of CD163+ 
and CD204+ M2-like macrophages25, suggesting that 
T2DM is associated with increased pro- inflammatory 
M1-like macrophage accumulation in pancreatic islets.
Obesity- associated islet inflammation. Islet inflam-
mation has been reported in individuals with obesity, 
characterized by the accumulation of immune cells10–12,29 
along with elevated production of inflammatory 
cytokines and chemokines29–31. Furthermore, studies 
have reported increased numbers of myeloid- lineage 
cells (primarily monocytes and macrophages) in the 
islets of obese animal models10,24,27,32. The first com-
prehensive analysis of obesity- associated islet macro-
phages used CD68 and CD11b as markers and found 
an increased number of macrophages in the pancreas 
of high- fat diet (HFD)-fed C57BL/6J mice and Goto–
Kakizaki rats24. Moreover, islets from individuals with 
T2DM released substantial amounts of inflammatory 
cytokines and chemokines such as IL-6, IL-8, CXCL1, 
granulocyte colony- stimulating factor (GCSF) and macro-
phage inflammatory protein 1α (MIP1α)24. Although 
these data showed a correlation between the abundance 
of macrophages and increased inflammatory cytokines, 
the cellular origins of these cytokines and their roles in 
β- cell function remained undetermined.
Further work has been carried out to characterize 
obesity- associated islet inflammation using various 
rodent models. For example, leptin receptor- deficient 
db/db mice, which are obese and used as a model of 
T2DM, have substantially increased accumulation 
of islet macrophages compared with wild- type mice. 
Further characterization showed that CD68+F4/80+ 
macro phages found in the pancreas of db/db mice exhi-
bited a pro- inflammatory M1-like phenotype32. In the 
same study, a new and less typical CD68+F4/80+ macro-
phage population was also found in the islets of humans 
with T2DM. Another study using a palmitate acid- induced 
obesity model reported that saturated fatty acids (SFAs) 
induced β- cells to produce chemokines that attracted 
CD11b+Ly6C+ M1-like pro- inflammatory monocytes 
and macrophages to the islets10. An in- depth assessment 
of obesity- associated metaflammation carried out using 
diet- induced and genetically induced mouse models 
of obesity found that obesity- associated islet inflam-
mation is dominated by macrophages, with negligible 
involvement of adaptive immune cells12 (Fig. 1).
Thus, macrophages in islets and in the exocrine 
stroma of the pancreas are distinct in origin and pheno-
typic properties. Whether this variation is due to loca-
tion or different lineages is uncertain; however, the 
Key points
•	Macrophages	are	the	primary	immune	cells	involved	in	obesity-	associated	islet	
inflammation	in	both	mice	and	humans.
•	Obesity	reprogrammes	the	islet	immune	microenvironment	by	inducing	the	local	
replication	of	islet-	resident	macrophages	or	by	recruiting	circulating	monocytes.
•	Islet	macrophages	in	obese	mice	display	multiple	functions,	including	decreasing	
β-cell	insulin	secretion	and	stimulating	β-	cell	proliferation.
•	In	the	normal,	lean	state,	islet	macrophages	promote	islet	development	and	
maintenance	of	normal	glucose-	stimulated	insulin	secretion.
•	Islet	macrophages	are	potential	therapeutic	targets	to	modulate	β-	cell	function	in	
individuals	with	obesity	and/or	type	2	diabetes	mellitus.
Yolk sac- derived primitive 
haematopoiesis
The generation of blood- 
lineage cells, including 
primitive erythroid cells, 
platelets and macrophages, in 
the extra- embryonic yolk sac 
during early embryonic 
development.
Osteopetrosis
A rare inherited syndrome 
characterized by increased 
bone density due to a defect of 
osteoclasts, a specialized 
population of macrophages 
that can resorb bone.
Insulitis
islet- specific inflammation 
characterized by the infiltration 
of various types of immune cell 
into pancreatic islets, more 
commonly used to describe 
the islet inflammation 
preceding or accompanying 
type 1 diabetes mellitus.
Islet amyloid polypeptide
(iAPP). An islet hormone that is 
co- secreted with insulin from 
β-cells and forms islet amyloids.
Metaflammation
Low- grade inflammation 
induced by overnutrition, 
which occurs in metabolic 
tissue (primarily adipose tissue, 
liver, muscle and pancreatic 
islets), causes dysregulation of 
immune cells and inflammatory 
responses.
www.nature.com/nrendo
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cellular reconstitution after irradiation experiments 
suggests that tissue location has a key role in pro-
gramming macrophages to gain specific phenotypes 
and functions12.
Causes of islet macrophage accumulation
Tissue- resident macrophages are populated from several 
waves of precursors during the embryonic stage and are 
self- maintained during adulthood13,33. However, during 
inflammation and tissue injury, bone marrow- derived 
monocytes can infiltrate tissues and differentiate into 
macrophages34.
Obesity induces local proliferation of islet macrophages. 
Interestingly, intra- islet and peri- islet macrophage 
populations are maintained in lean mice at a very low 
turnover rate12. This finding is consistent with a pre-
vious report showing that, at steady state, islet macro-
phages are only minimally derived from circulating 
blood cells and instead replicate locally at a low rate17. 
However, under obese conditions, local proliferation 
of islet- resident macrophages in mice was substantially 
increased12. These findings suggest a new mechanism 
of intra- islet macrophage accumulation in obese mice. 
Local proliferation has also been demonstrated for adi-
pose tissue macrophages (ATMs) under obese condi-
tions in mice35–38. In addition, reports suggest that IL-6 
(reF.35), CCL2 (reF.37), CSF1 (reF.39) or osteopontin38 could 
stimulate ATM replication in animals.
Macrophages can adapt to local environmental 
cues40,41 and intra- islet-resident macrophage prolifer-
ation could possibly be an adaptive response to patho-
physiological stimuli. However, the factors that mediate 
this adaptation remain to be defined. An interesting 
question is whether elevated plasma glucose and/or 
fatty acid levels in obesity can trigger the release of 
stimulating factors within the islets that activate the local 
proliferation of islet macrophages.
Circulating monocytes and islet macrophages. During 
chronic inflammation, circulating monocytes infiltrate 
and accumulate in inflamed tissue sites. Whether an 
infiltration of circulating monocytes can also explain 
obesity- associated islet inflammation is an important 
question. In a SFA treatment mouse model, ethyl pal-
mitate infusion significantly increased the number of 
CD11b+Ly6C+ monocytes found in pancreatic islets10. 
However, the exact distribution of these monocytes 
(that is, intra- islet or peri- islet) was not determined. 
Importantly, adoptive transfer experiments showed 
that transferred fluorescently labelled Ly6C+ mono-
cytes infiltrated to the boundary between the exo-
crine and endocrine pancreas but did not penetrate 
into the islets in HFD- fed obese mice12. Furthermore, 
these transferred cells retained their monocyte pheno-
type and did not differentiate into macrophages in the 
pancreas. Interestingly, time- course analysis showed 
that these peri- islet monocytes eventually migrate to 
pancreas- draining lymph nodes12 (Fig. 1). However, the 
lack of penetration of transferred monocytes into 
the HFD islets might be due to the lack of an avail-
able tissue niche. Indeed, a previous study reported that 
monocytes can replace islet macrophages in mice after 
lethal irradiation17.
The initiating factors for islet inflammation. An impor-
tant and unanswered question is what triggers islet 
inflammation in obesity. As obesity is associated with 
systemic low- grade inflammation, systemic metabolic 
or inflammatory factors could potentially impinge 
on the islet microenvironment. For example, in vitro 
high- glucose stimulation can induce IL-1β secretion 
from islets through activation of the NLRP3 inflam-
masome42,43. Circulating SFAs could also induce islet 
inflammation, particularly in the presence of hyper-
glycaemia10,44,45. Although circulating cytokine levels 
are often increased in obesity and diabetes mellitus, 
these cytokines serve primarily as biomarkers of sys-
temic inflammation, as the concentration of circulating 
cytokines is much lower than the biologically active levels 
that occur within the local tissue microenvironment. The 
blood concentration of cytokines such as tumour necro-
sis factor (TNF) or IL-1β are 10-fold to 100-fold lower 
than the levels required to induce pro- inflammatory 
biological effects and are therefore unlikely to trigger 
obesity- induced islet inflammation46–50.
Alternatively, islet- derived local signals could also 
have an important role in initiating the inflammatory 
cascade51. For example, islet- resident macrophages could 
act as first- line responders to sense systemic metabolic 
changes. As a consequence, these macrophages could 
alter their function and/or expand locally. However, 
β-cells have been suggested to be early responders 
(mentioned earlier in the Review) as these cells can sense 
excessive fatty acids and produce chemo kines to recruit 
Ly6C+ monocytes and macrophages to pancreatic islets10. 
Moreover, ATP released from stressed β- cells has been 
reported to lead to macrophage activation52.
In patients with T2DM, aggregated IAPP can induce 
pro- inflammatory responses in islet macrophages. For 
example, synthetic human IAPP (hIAPP) treatment or 
the use of an hIAPP transgenic mouse model showed 
that hIAPP can increase the synthesis of IL-1β in islet- 
resident macrophages53. Whether islet macrophages, 
β-cells or both are the first responders to metabolic 
insults remains unclear; however, local interactions 
between these two cell types seem to accelerate the 
inflammatory process.
Box 1 | Physiological and pathophysiological roles of islet macrophages
noninflammatory state
•	Intra-	islet	macrophages	and	peri-	islet	macrophages12,17
•	Supports	islet	(β-	cell)	development	and	regeneration15–17
•	Promotes	glucose-	stimulated	insulin	secretion12
•	Low	concentration	of	IL-1β10,17,104,109
obesity and type 2 diabetes mellitus
•	Increased	number	of	intra-	islet	macrophages10,12,24,27,32
•	Promotes	compensatory	β-	cell	proliferation12
•	Suppresses	glucose-	stimulated	insulin	secretion	with	decreased	expression	of	
β-cell-specific	genes10,12,61,62
•	Elevated	production	of	IL-1β10,51,61
Nature reviews | Endocrinology
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Transcriptional profile of islet macrophages. Obesity 
affects islet macrophage transcriptomes, which results 
in altered functions. Earlier studies reported that 
macro phages within the islets of obese mice exhibited 
a pro- inflammatory, M1-like phenotype10,32. However, a 
2015 study found that, in lean mice, islet- resident 
macro phages constitutively expressed M1-associated 
cytokines, including IL-1β and TNF17. Furthermore, in a 
2019 study12, RNA sequencing analysis of isolated 
macro phages from lean and obese mice showed no clear 
shift between M1-like and M2-like profiles in either 
intra- islet or peri- islet macrophage subsets. Interestingly, 
islet macrophages in leptin receptor- deficient db/db mice 
have been proposed to show a shift from an early stage 
(8 weeks of age) pro- inflammatory phenotype towards 
late- stage (28 weeks of age) profibrotic characteristics32. 
Thus, during the development of obesity and T2DM, the 
nature of islet inflammation is not simply polarization 
from an M2-like to an M1-like state (Box 2) but instead 
is a mixed continuum of heterogeneous cell phenotypes. 
Consistent with this notion, in adipose tissue of obese 
mice, ATMs exhibit diverse phenotypes across a broad 
spectrum of M1-like and M2-like polarization states54–56.
Other immune and nonimmune cells. A few studies 
reported the presence of T cells and B cells29,57 in pan-
creatic islets of humans with T2DM. By contrast, another 
study did not detect the presence of T cells or B cells 
in the islets of HFD- fed mice, which is evidence against 
the involvement of the adaptive immune system in 
obesity- associated islet pathology12. However, T cells 
can be detected in the exocrine pancreas at very low 
abundancy, and a HFD did not alter their number12. 
Another study reported that type 2 innate lymphoid cells 
(ILC2s) were present in the islets of lean mice and that 
an HFD reduced the number of these cells in the islets. 
These cells stimulated insulin secretion through retinoic 
acid produced by islet myeloid cells58. Furthermore, an 
IL-33–ILC2 axis was activated after acute β- cell stress 
but was defective during chronic obesity58. Thus, other 
types of immune cell might be involved in obesity- 
associated islet inflammation in a model- or stage- 
dependent manner. In addition, islet endothelial cells 
and neurons also have important roles in modulating 
the islet microenvironment, which can influence β-cell 
function52,59. For example, central nervous system mod-
ulation of islet function has been reported, and islet 
endothelial cell- derived vascular endothelial growth 
factor (VEGF) might affect β- cell replication60 (also see 
the section on Recovery of β- cell mass after injury or 
acute β- cell depletion).
Effects on β- cell function
The following section discusses potential effects of islet 
macrophages on β- cell function. The deficit of β- cell 
function in T2DM is characterized by decreased 
β- cell mass and impaired glucose- stimulated insulin 
secretion (GSIS)61. Incubation of primary human islets 
or β- cell lines with pro- inflammatory cytokines, such as 
IL-1β or TNF, increases β- cell apoptosis and decreases 
GSIS62. By contrast, clodronate liposome- mediated 
depletion of macrophages in the islets of HFD- fed mice 
improves GSIS12. Consistent with this finding, systemic 
depletion of tissue macrophages by in vivo administra-
tion of clodronate liposomes improves glucose tolerance 
in obese mice10. The full mechanisms by which islet 
macrophages impair GSIS are not clearly understood; 
however, it probably involves both macrophage- derived 
soluble factors and direct cell–cell contact between islet 
macrophages and β- cells (Fig. 2).
Soluble factors. The levels of several cytokines, such 
as TNF and IL-1β, are increased in obese and T2DM 
islets in humans and suppress β- cell GSIS62,63. The best- 
studied cytokine produced by islet macrophages is IL-1β. 
Of note, β- cells express the IL-1 receptor (IL-1R) and 
obesity increases IL-1β expression in islet macrophages 
in both mice and humans10,64. In vitro incubation of 
mouse and human monocyte/macrophage cell lines in 
media containing high concentrations of glucose or free 
fatty acids (FFAs) induces increased IL-1β production. 
This suggests that metabolic stress in obesity and/or 
T2DM can stimulate islet macrophages to produce more 
IL-1β10,65,66. Indeed, while both β- cells and macrophages 
can produce IL-1β, macrophages are seemingly the 
major source of islet IL-1β production in obesity10,64.
Incubation of primary human or mouse islets, 
or β- cell lines, with IL-1β decreases GSIS and increases 
β-cell apoptosis62. Moreover, the secretion of inflamma-
tory cytokines from islet macrophages that are cocul-
tured with Min6 cells amplifies the lipotoxic effects 
of chronic palmitate treatment, decreasing GSIS and 
expression of the genes involved in β- cell differentia-
tion and function10. Furthermore, the increased lipotoxic 
Type 2 innate lymphoid cells
(iLC2s). A subgroup of innate 
lymphoid cells characterized 
by the lack of rearranged 
receptors and production of 
type 2 cytokines such as iL-5 
and iL-13.
Box 2 | Protective and harmful inflammation
Inflammation	is	an	adaptive	response	exploited	by	
the host	to	deal	with	harmful	conditions22.	Acute	
inflammation	is	commonly	associated	with	infection,	
whereas	chronic	inflammation	is	widely	associated	
with more	complex	disorders,	such	as	diabetes	mellitus	
and	cardiovascular	diseases18,19,21.	Evolutionarily,	
inflammation	is	a	beneficial	protective	mechanism	to	
eliminate	infectious	pathogens,	elicit	tissue	repair	and	
restore	tissue	homeostasis22.	By	contrast,	chronic,	low-	
grade	inflammation	is	generally	thought	to	result	in	
pathological	consequences	in	the	targeted	tissue	or	cell,	
such	as	functional	impairment,	cell	death	and	tissue	
damage9.
Macrophages	are	key	players	in	orchestrating	
the initiation,	specification	and	resolution	of	tissue	
inflammation9,22,23.	Macrophages	are	heterogenous	in	
terms	of	their	origin,	tissue	phenotype	and	function124.	
By adapting	to	tissue	environmental	cues,	macrophages	
can	acquire	different	functionalities	and	are	programmed	
into	pro-	inflammatory	(sometimes	referred	to	as	M1-like),	
anti-	inflammatory	(sometimes	referred	to	as	M2-like)	or	
reparative	states.
Dissecting	the	phenotypic	and	functional	
heterogeneity	of	islet	macrophages	and	the	interactions	
between	macrophages	and	β-	cells	will	improve	our	
understanding	of	obesity	and	type	2	diabetes	mellitus.	
This	knowledge	could	lead	to	the	development	of	new	
immunomodulatory	regimens	to	prevent	or	reverse		
these	disorders.
www.nature.com/nrendo
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effects of FFAs on β- cells by coculture with macrophages 
is ameliorated by the addition of neutralizing antibodies 
against the pro- inflammatory cytokines TNF and IL-1β 
to the culture media10.
The intracellular events through which inflamma-
tion impairs β- cell function involve the JNK and nuclear 
factor- κB (NF- κB) signalling pathways. For example, 
TNF- induced NF- κB activation in INS-1 rat insulinoma 
cells decreases GSIS67. In addition, activation of NF- κB 
in β- cells can reduce expression of an ER Ca2+ pump 
(sarcoplasmic reticulum Ca2+ ATPase type 2b), which 
leads to ER stress and decreased GSIS68.
Unlike TNF and IFNγ, IL-1β also stimulates JNK in 
β- cell lines69–72. IL-1β- induced JNK activation decreases 
GSIS by suppressing the insulin receptor substrate 
(IRS)–phosphoinositide 3-kinase (PI3K)–AKT signal-
ling pathway. This results in reduced FOXO1 phospho-
rylation, with increased nuclear localization of active 
FOXO1 and decreased DNA binding to PDX1 (reFs73–75). 
These findings are important as research suggests that 
normal FOXO1 function is necessary for maintenance of 
the full β- cell differentiation state76. In addition, a study 
showed that combination IL-1β–TNF–IFNγ treatment 
of human islets and INS-1 cells can result in β- cell apop-
tosis by inducing mitochondrial stress and activation of 
proapoptotic BCL-2 family proteins77.
IL-1β treatment of primary rat β- cells does not fully 
recapitulate the gene expression changes induced by glu-
colipotoxicity, which suggests that some divergence of 
mechanisms might also exist78,79. Another study reported 
data that questioned the importance of IL-1β in human 
islets, showing that in vitro treatment with high glu-
cose concentrations (11 and 28 mmol/l), did not induce 
IL-1β production or NF- κB activation80. Together, 
these results indicate the existence of other factors and 
mechanisms involved in high glucose or FFA- induced 
β-cell dysfunction.
Cell–cell contacts. Another mechanism by which macro-
phages can decrease β- cell insulin secretion is through 
direct cell–cell contact. For example, co- incubation of 
the Min6 β- cell line with intra- islet macrophages iso-
lated from HFD- fed mice decreases GSIS12. Interestingly, 
this effect was seen only when the macrophages were 
directly added to the Min6 cells. Preventing direct 
cell–cell contact by culturing the two cell types in 
Transwell plate chambers, which still allow interactions 
through soluble factors, blocks the impairment in 
GSIS12. These results suggest that the inhibitory effect of 
intra- islet macrophages on β- cell GSIS includes a cell–
cell contact process. The concept of β- cell–macrophage 
interactions through direct cell–cell contacts is not new. 
Islet macrophages can engulf insulin secretory vesicles 
in a mouse model of T1DM81. Similar to these findings, 
mouse intra- islet macrophages contain intact insulin 
secretory vesicles, and the number of engulfed vesicles 
was greatly increased in obesity12.
The mechanism by which islet macrophages incorpo-
rate insulin secretory vesicles from β- cells and how obe-
sity accelerates this process remains unclear. However, 
macrophages can generate open- ended channels called 
tunnelling nanotubes, which transport cytoplasmic 
materials between connected cells82. Therefore, tunnel-
ling nanotubes could theoretically mediate macrophage 
uptake of β- cell secretory granules, and obesity and islet 
inflammation might increase this process (Fig. 2). The 
potential transport of macrophage- derived factors to 
β- cells through these nanotubes might also affect β- cell 
insulin secretion. It is also possible that extracellular 
vesicles or gap junctions are involved in the crosstalk 
between macrophages and β- cells.
Effects on β- cell proliferation
In adult humans, the turnover rate of β- cells is extremely 
low. However, β- cells are not permanently quiescent. 
Under certain conditions, such as pregnancy and obesity, 
these cells are able to re- enter the cell cycle12,83. In addi-
tion, adaptive expansion of β- cell mass has been observed 
in obese, insulin- resistant mice and humans84–88. Multiple 
factors, including increased plasma glucose concentra-
tions89–91, insulin92 and expression of hepatocyte growth 
factor93–95, can stimulate β- cell replication. Evidence 
now exists suggesting that macrophages can have an 
important role in β- cell replication.
Recovery of β- cell mass after injury or acute β- cell deple-
tion. An increasing body of evidence has supported a role 
for macrophages in β- cell expansion. For example, in a 
pancreatic injury mouse model induced by partial duct 
ligation, islet macrophages were observed to increase 
β- cell proliferation through transforming growth 
factor (TGF) and downstream SMAD7 signalling96. 
Lean Obese
Draining
lymph nodes
↑ β-Cell
proliferation
↑ ii-mac
proliferation
α-Cell
α/β-Cell
β-Cell
δ-Cell
Monocyte
Circulating
monocytepi-mac
ii-mac
Fig. 1 | Macrophages dominate obesity- associated islet inflammation. A comparison of 
mouse islets between lean and obese conditions. In lean mice, two major populations  
of macrophages can be detected based on their anatomical distributions: peri- islet 
macro phages (pi- macs; F4/80hiCD11c–) and intra- islet macrophages (ii- macs; 
F4/80loCD11chi)12. Both populations are islet- resident cells. By contrast, in obesity ,  
the size of islets is increased owing to increased β- cell replication and cell size. 
Different mechanisms have been proposed to explain obesity- associated macrophage 
accumulation in the islet. In one model, stressed β- cells recruit circulating monocytes, 
which differentiate into pro-inflammatory macrophages after infiltrating into the islets. 
This model has been challenged by other studies showing that even though monocytes 
can be detected in the pancreas they do not infiltrate into the islets10. Instead, the 
accumulation of ii- macs is caused by local proliferation of resident macrophages12.
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permeable to soluble factors 
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By contrast, depletion of islet macrophages in vivo in 
a mouse model, or ex vivo in isolated pancreatic islets, 
by clodronate liposome treatment results in a decreased 
number of proliferating bromodeoxyuridine-positive 
β- cells96.
Using a mouse model with 50% β- cell depletion, fol-
lowed by β- cell-specific overexpression of connective tis-
sue growth factor, researchers found that β- cells release 
connective tissue growth factor as a chemoattractant to 
recruit macrophages, which then facilitate the recovery 
of β- cell mass97. In another study, transiently increased 
expression of VEGFA in β- cells led to β- cell loss, and 
withdrawal of VEGFA stimulated a robust but transient 
increase in the proliferation of pre- existing β- cells59. 
Moreover, bone marrow- derived macrophages were 
recruited to the site of β- cell injury and are important 
for β- cell proliferation59. Taken together, these studies 
indicate that macrophages have a critical role in main-
taining steady state β- cell mass and facilitate increased 
β- cell proliferation and mass in pathophysiological 
insulin- resistant states.
β- Cell proliferation in obesity. Obesity- induced insulin 
resistance induces an expansion of pancreatic β- cells, 
which compensate by secreting increased quantities of 
insulin. Islet macrophages from obese mice show an 
increased capacity to stimulate β- cell proliferation and 
both intra- islet and peri- islet macrophages show simi-
lar effects. This effect was mediated by platelet- derived 
growth factor (PDGF)–PDGF receptor (PDGFR) sig-
nalling12. Thus, the PDGF–PDGFR pathway has an 
important role in mouse and human β- cell prolifer-
ation98. Of note, one study suggests that the reduction 
of PDGFR signalling in β- cells accounts for the decline 
in β- cell replication in aged mice and older humans98. 
Macrophages are a major source of PDGF99–102 and the 
expression of Pdgfa was increased in both CD11c+ intra- 
islet macrophages and CD11c– peri- islet macrophages in 
obese mice12. Furthermore, inhibition of PDGFR signal-
ling in vitro with a small- molecule inhibitor, CP-673451, 
blocked the effect of islet macrophages to stimulate 
β-cell replication12. Therefore, in addition to the expres-
sion of PDGFR on β- cells, the production of PDGF by 
islet macrophages forms a signalling system that induces 
β- cell proliferation (Fig. 2).
Proinflammatory cytokines. Proinflammatory cyto-
kines, such as TNF and IL-1β, are key components of 
the islet inflammatory microenvironment31, and the role 
of IL-1β has been extensively studied103. Knockout of 
β- cell IL-1R in vivo causes β- cell dedifferentiation104. 
In addition, low concentrations (0.01–0.02 ng/ml) of 
IL-1β can induce β- cell proliferation in vitro by activating 
the FAS–FLIP antiapoptotic pathway105. Moreover, lean 
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Fig. 2 | interactions of islet macrophages and β- cells in obesity. An increasing body of evidence supports the idea that 
islet macrophages influence β- cells in multiple ways. In obesity , elevated plasma levels of glucose and free fatty acids 
(FFAs) can induce a pro- inflammatory phenotype of islet macrophages. As a result, macrophages produce increased 
amounts of pro- inflammatory cytokines such as IL-1β and tumour necrosis factor (TNF). These cytokines activate nuclear 
factor- κB (NF- κB) and JNK pathways in β- cells and also exacerbate endoplasmic reticulum (ER) stress (1)67,68. Synergistically , 
these responses dampen β- cell glucose- stimulated insulin secretion (GSIS). In addition to inflammatory cytokines, other 
mechanisms involving macrophage- mediated β- cell dysfunction exist. The mechanisms include extracellular vesicles 
containing insulin released by β- cells and phagocytosed by islet macrophages (2)12; and the formation of tunnelling 
nanotubes (3) or gap junctions (4) between macrophages and β- cells, allowing for bidirectional exchange of cellular 
contents. Obesity increases platelet- derived growth factor (PDGF) expression in islet macrophages via unclear mechanisms12. 
Through PDGF receptors (PDGFRs) expressed in β- cells, PDGF promotes β- cell proliferation by activating downstream 
extracellular signal- regulated kinase (ERK) signalling and inducing cell cycle gene (for example, Ccnd1) expression (5)98. 
MD2, myeloid differentiation factor 2; TLR4, Toll- like receptor 4.
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mice that lack IL-1β production show downregulation 
of FAS–FLIP activation as well as decreased β- cell 
proliferation105.
In contrast, at high concentrations (1 ng/ml), IL-1β 
can suppress the expression of genes associated with 
a fully differentiated β- cell phenotype in human and 
mouse islets106. This effect can facilitate β- cell apop-
tosis and can also induce β- cell dedifferentiation into 
islet endocrine cells, which express and secrete both 
insulin and glucagon107. These latter dual- positive 
endocrine cells107 generally demonstrate impaired GSIS 
in vivo, which provides another potential mechanism 
whereby IL-1β adversely effects β- cell GSIS106. Given 
all of these findings, the IL-1β ‘tone’ within the islet 
provides an important control point for regulation of 
β- cell mass.
In humans, iL-1 receptor antagonist (IL-1Ra) expres-
sion is increased in the blood during obesity and T2DM 
but is decreased in islets from patients with T2DM108,109. 
In mice, β- cell-specific IL-1Ra ablation resulted in a 
reduction in β- cell proliferation and impaired insu-
lin secretion109. In addition, decreased plasma levels 
of IL-1Ra promotes IL-1β signalling and studies have 
shown that treatment of Goto–Kakizaki rats with IL-1Ra 
led to a reduction in islet inflammation and improved 
β- cell GSIS. Taken together, these results provide compel-
ling evidence for the role of the inflammatory cytokine 
IL-1β in islet inflammation and β- cell dysfunction.
Beneficial effects on β- cells
While depletion of islet macrophages improves GSIS in 
HFD- fed obese mice, macrophage depletion decreases 
β- cell GSIS in normal islets from lean chow- fed mice12. 
This finding suggests that, in the normal lean state, islet 
macrophages might have a beneficial role in β- cell insu-
lin secretion. The mechanism (or mechanisms) by which 
islet macrophages from lean and obese mice have seem-
ingly opposite roles in β- cell function remains unclear. 
In obesity, islet macrophages might be reprogrammed 
to impair β- cell GSIS, which could be due to effects of 
FFAs, glucose or cytokines, such as IL-1β.
One possible explanation for the metabolism- 
dependent effects of islet macrophages is the level of 
IL-1β that they produce. For example, islet macrophages 
in nonobese mice exhibit a pro- inflammatory activation 
state and produce IL-1β17. However, the acute postpran-
dial rise in IL-1β production by myeloid cells has been 
demonstrated to contribute to meal- induced insulin 
secretion in a fasting–refeeding mouse model and is nec-
essary for normal glycaemic control110. In line with this, 
IL-1R1-deficient mice exhibited an impaired adaptive 
increase in plasma insulin levels after HFD feeding111. 
However, chronic accumulation or elevated production 
of IL-1β (mainly by islet macrophages) is detrimental to 
β- cell GSIS103.
In addition to IL-1β, other factors and mechanisms 
could also have a role in shifting the effect of islet macro-
phages on β- cells. For instance, pathways related to syn-
apse formation were more activated in islet macrophages 
in obese mice than in lean mice12, suggesting that obe-
sity alters cell–cell interaction between macrophages 
and β- cells.
The above discussion raises several questions. First, 
what induces islet macrophages to change their effects 
on β- cell GSIS in the transition from the lean to the obese 
state? Second, at which stage of obesity does this func-
tional switch of islet macrophages happen? Third, what 
modifications can reverse the macrophage- mediated 
‘detrimental’ effects on β- cells? To answer these ques-
tions, it will be necessary to perform longitudinal stud-
ies that can elucidate the functional properties of islet 
macro phages and assess the effects of these cells on β- cell 
function in a stage- dependent manner.
Lipids as mediators of crosstalk
Several studies have indicated that SFAs and potentially 
lipoproteins are circulating factors that might contrib-
ute to islet inflammation, β- cell dysfunction and β- cell 
hyperplasia10,44,45. For example, experimental elevation 
of palmitate levels in mice induces islet inflammation10. 
Moreover, the same study showed that in vivo treatment 
with SFAs increased the accumulation of islet macro-
phages and other markers of islet inflammation and also 
decreased GSIS.
SFAs activate intracellular pro- inflammatory path-
ways by binding to the innate immune receptor Toll- 
like receptor 4 (TLR4). Studies show that TLR4 is 
required for the SFA- induced effect on islet inflam-
mation and further show that TLR4 expressed on islet 
macrophages was essential for this process10. The SFAs 
act on macrophage TLR4 to stimulate the NF- κB path-
way, resulting in cytokine secretion, particularly of IL-1β 
and TNF, which can negatively influence β- cell GSIS10. 
TLR4 is also expressed on β- cells, and SFAs can bind to 
this receptor and induce β- cells to secrete chemokines 
and other factors, which stimulate islet macrophage 
accumulation10.
In addition to these effects of SFAs on β- cell secre-
tory functions, elevated SFA levels can also affect β- cell 
proliferation10. This effect is particularly true when ele-
vated SFA levels are combined with hyperglycaemia, 
as this combination appears to cause additive effects 
on β- cell proliferation. Of note, apoptosis negatively 
regulates overall β- cell mass and, within the islet, SFAs 
can be converted to ceramides, which induce apopto-
sis112,113. Furthermore, exposure to palmitate is reported 
to trigger human β- cell apoptosis by inducing death 
protein 5-mediated ER stress114. Thus, by inducing apop-
tosis and stimulating proliferation, SFAs might have 
important effects on increasing overall β- cell mass in 
the context of obesity and T2DM.
Another interesting connection between circulat-
ing lipoproteins and β- cell function has been reported. 
LDL receptor- related protein 1 (LRP1) can interact with 
extracellular lipoproteins, and one research group gener-
ated β- cell-specific LRP1-deficient mice and showed that 
these animals were partially protected from the adverse 
effects of a HFD on β- cell insulin secretion, as well as 
HFD- induced β- cell hyperplasia45. The same study also 
found that this could be related to the effect of LRP1 
deletion to upregulate β- cell peroxisome proliferator- 
activated receptor- γ2 (PPARγ2) in HFD- fed mice, as 
transgenic overexpression of PPARγ2 in β- cells partially 
recapitulated the LRP1 phenotype.
IL-1 receptor antagonist
(iL-1ra). A member of the iL-1 
family of cytokines that binds 
to the iL-1 receptor but does 
not induce intracellular 
signalling.
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Senescence
Cellular senescence is characterized by stable cell cycle 
arrest and a pro- inflammatory senescence- associated 
secretory phenotype115. The current theory is that the 
senescent signal can spread from one senescent cell 
to other surrounding cells; however, the mechanism 
remains to be resolved. Some indications suggest 
that individuals with T1DM and the nonobese dia-
betic (NOD) mouse model harbour a set of senescent 
β- cells that express increased levels of the prosurvival 
mediator BCL-2 (reF.116). Interestingly, treatment with a 
BCL-2 inhibitor can efficiently deplete senescent β- cells 
and prevent the occurrence of T1DM in the NOD 
mouse model116.
Obesity could potentially induce a β- cell senescence 
response, which might drive the pathogenesis of T2DM. 
For example, an earlier study found that the number 
of acidic β- galactosidase-positive senescent β- cells was 
increased in HFD- fed mice117. More recently, a 2017 
study found that insulin resistance can induce a senescent 
state in both mouse and human β- cells, which leads to 
decreased insulin secretion118. Consistent with this idea, 
the number of senescent β- cells is increased in islets from 
patients with T2DM118. However, it remains unknown 
whether islet macrophages also develop senescent pheno-
types in the context of obesity or whether senescent 
β- cells can regulate islet macrophage activation.
Clinical studies
A number of clinical trials targeting inflammatory 
pathways have been tested in patients with T2DM, 
including the salicylic acid derivative salsalate and 
anti- inflammatory TNF inhibitors119,120. In some clin-
ical trials, the effects of these interventions on β- cells 
have been assessed. For example, in one double- blind, 
parallel group trial involving 70 patients with T2DM, 
the administration of the recombinant IL-1Ra anakinra 
confers a moderate but statistically significant decrease 
in fasting blood glucose and HbA1c (–0.3 to –0.4%) 
levels121. Furthermore, anakinra treatment increases 
insulin secretion from β- cells without affecting insu-
lin sensitivity. The larger scale CANTOS trial included 
individuals with prior myocardial infarction and high- 
sensitivity C- reactive protein and used an anti- IL-1β 
antibody (canakinumab)122. They demonstrated that 
IL-1β neutralization lowers plasma HbA1c levels dur-
ing the first 6–9 months of treatment but does not 
reduce the incidence of new- onset diabetes mellitus122. 
As canakinumab treatment substantially reduces the 
recurrence of cardiovascular events, these results sug-
gest that anti- inflammatory therapy can provide bene-
ficial effects for individuals with obesity and/or T2DM. 
A meta- analysis performed in 2019 of 2,921 individuals 
from eight phase I–IV studies found a statistically signif-
icant overall HbA1c- lowering effect of IL-1 antagonism, 
achieved through either anti- IL-1 antibodies or IL-1R 
antagonists123. In this meta- analysis, a statistically sig-
nificant correlation between baseline C- reactive protein 
and C- peptide, and HbA1c outcomes was also revealed. 
However, the authors also cautioned that the identi-
fication of further biomarkers is needed to define the 
potential of anti- IL-1 therapies in T2DM.
Conclusions
Islet inflammation has emerged as a key feature of obe-
sity and T2DM; in these conditions islet macrophages 
are the defining immune cell type. Although much has 
been learned about macrophage–β- cell inter actions, 
many important questions remain unresolved. For 
example, the triggering events with respect to islet 
macrophage proliferation and expansion are unclear. 
Moreover, it is not clear whether the initiating signals 
are derived from the β- cell or whether they are extrinsic 
to the islet. Of note, islet macrophage proliferation is not 
significantly increased in mice until after 12–16 weeks 
of an HFD12. If β- cell insulin secretory function is 
affected prior to this time, then what is the cause? Have 
macrophages already started to reprogramme into a 
pathogenic phenotype before proliferation ensues or 
does a macrophage- independent mechanism cause 
the initial defect in GSIS? In addition, it is not cur-
rently clear why circulating monocytes migrate to the 
peri- islet area but do not enter the islets. Finally, more 
information is needed on the role of islet inflammation 
and macrophages in the insulin secretory defects that 
characterize human T2DM.
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